Alice Y. Zhou

4.7k total citations · 1 hit paper
31 papers, 1.4k citations indexed

About

Alice Y. Zhou is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Alice Y. Zhou has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Immunology and 9 papers in Molecular Biology. Recurrent topics in Alice Y. Zhou's work include CAR-T cell therapy research (10 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Glioma Diagnosis and Treatment (5 papers). Alice Y. Zhou is often cited by papers focused on CAR-T cell therapy research (10 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Glioma Diagnosis and Treatment (5 papers). Alice Y. Zhou collaborates with scholars based in United States, Croatia and Japan. Alice Y. Zhou's co-authors include Kimberly M. Davis, Jeffrey N. Weiser, S. E. Lysenko, Yimin Yu, Thomas B. Clarke, Douglas B. Johnson, Sandra Ryeom, Russell Dinnage, Omar H. Butt and Mark D. Hunter and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Alice Y. Zhou

29 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity

2010 901 citations Thomas B. Clarke, Kimberly M. Davis et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alice Y. Zhou United States	14	669	460	256	212	142	31	1.4k
David S. Donaldson United Kingdom	15	598 0.9×	487 1.1×	128 0.5×	177 0.8×	99 0.7×	29	1.4k
Nicolas Tchitchek France	23	596 0.9×	589 1.3×	137 0.5×	364 1.7×	327 2.3×	74	1.8k
Giulia Nigro France	20	934 1.4×	304 0.7×	378 1.5×	258 1.2×	152 1.1×	40	1.7k
Jennifer L. Owen United States	20	611 0.9×	288 0.6×	195 0.8×	125 0.6×	66 0.5×	33	1.2k
Moira Paroni Italy	27	722 1.1×	762 1.7×	164 0.6×	140 0.7×	189 1.3×	39	1.9k
Motohiko Kadoki Japan	9	402 0.6×	852 1.9×	122 0.5×	236 1.1×	163 1.1×	14	1.4k
Benjamin Wahl Germany	16	615 0.9×	1.1k 2.3×	149 0.6×	156 0.7×	108 0.8×	18	2.0k
Jamie Schoenborn United States	5	452 0.7×	970 2.1×	278 1.1×	148 0.7×	215 1.5×	7	1.7k
Claire E. O’Leary United States	16	506 0.8×	758 1.6×	146 0.6×	172 0.8×	114 0.8×	19	1.6k
Ludovic Huot France	20	862 1.3×	381 0.8×	134 0.5×	162 0.8×	333 2.3×	30	1.6k

Countries citing papers authored by Alice Y. Zhou

Since Specialization

Citations

This map shows the geographic impact of Alice Y. Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice Y. Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice Y. Zhou more than expected).

Fields of papers citing papers by Alice Y. Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice Y. Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice Y. Zhou. The network helps show where Alice Y. Zhou may publish in the future.

Co-authorship network of co-authors of Alice Y. Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Alice Y. Zhou. A scholar is included among the top collaborators of Alice Y. Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alice Y. Zhou. Alice Y. Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adeyelu, Tolulope, Andrew Elliott, Farah Abdulla, et al.. (2024). ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes. Scientific Reports. 14(1). 3444–3444. 6 indexed citations

Cubitt, Celia C., Pamela Wong, Jennifer A. Foltz, et al.. (2024). Induced CD8α identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation. Journal of Clinical Investigation. 134(15). 3 indexed citations

Zhou, Alice Y., et al.. (2024). Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma. Frontiers in Oncology. 14. 1385094–1385094. 2 indexed citations

O’Neal, Julie, Matthew Cooper, Julie Ritchey, et al.. (2023). Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc. Blood Advances. 7(20). 6009–6022. 20 indexed citations

Zhou, Alice Y., et al.. (2023). BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series. Journal of the National Comprehensive Cancer Network. 21(10). 991–999.

Adeyelu, Tolulope, Andrew Elliott, Soo J. Park, et al.. (2023). Homologous Recombination Deficiency (HRD) in Cutaneous Oncology. International Journal of Molecular Sciences. 24(13). 10771–10771. 8 indexed citations

Zhou, Alice Y., et al.. (2023). Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity. Journal of the National Comprehensive Cancer Network. 21(7). 688–693.e3. 8 indexed citations

Butt, Omar H., Alice Y. Zhou, Beau M. Ances, John F. DiPersio, & Armin Ghobadi. (2023). A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Frontiers in Neurology. 14. 1110647–1110647. 16 indexed citations

Khaddour, Karam, et al.. (2022). Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. Frontiers in Oncology. 12. 978996–978996. 6 indexed citations

10.

Marín, Nancy D., Bradley A. Krasnick, Michelle Becker‐Hapak, et al.. (2021). Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clinical Cancer Research. 27(17). 4859–4869. 44 indexed citations

11.

Butt, Omar H., Alice Y. Zhou, Jiayi Huang, et al.. (2021). A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab164–vdab164. 38 indexed citations

12.

Butt, Omar H., Alice Y. Zhou, Paolo F. Caimi, et al.. (2021). Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study. Blood. 138(Supplement 1). 2841–2841. 2 indexed citations

13.

Zhou, Alice Y., Daniel Wang, Svetlana B. McKee, et al.. (2019). Correlates of response and outcomes with talimogene laherperpvec. Journal of Surgical Oncology. 120(3). 558–564. 19 indexed citations

14.

Kim, Dae Won, Neil J. Shah, Robert M. Conry, et al.. (2017). Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.. Journal of Clinical Oncology. 35(15_suppl). 9566–9566. 6 indexed citations

15.

Schuster, Stephen J., Jakub Svoboda, Sunita D. Nasta, et al.. (2016). Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).. Journal of Clinical Oncology. 34(15_suppl). 7564–7564. 7 indexed citations

16.

Schadler, Keri, Erika J. Crosby, Alice Y. Zhou, et al.. (2014). Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell–Derived Thrombospondin-1. Cancer Research. 74(8). 2171–2181. 14 indexed citations

17.

Zhou, Alice Y. & Sandra Ryeom. (2014). Cyclosporin A Promotes Tumor Angiogenesis in a Calcineurin-Independent Manner by Increasing Mitochondrial Reactive Oxygen Species. Molecular Cancer Research. 12(11). 1663–1676. 22 indexed citations

18.

Alvarez, James V., Tien-Chi Pan, Jason R. Ruth, et al.. (2013). Par-4 Downregulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy. Cancer Cell. 24(1). 30–44. 68 indexed citations

19.

Clarke, Thomas B., Kimberly M. Davis, S. E. Lysenko, et al.. (2010). Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nature Medicine. 16(2). 228–231. 901 indexed citations breakdown →

20.

Schwarz, Jürgen, et al.. (2001). Effect of Fusarium graminearum and F. Poae infection on barley and malt quality. 54. 55–63. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact